Cost effectiveness of management of mild-to-moderate atopic dermatitis with 1% pimecrolimus cream in children and adolescents 2-17 years of age

American Journal of Clinical Dermatology

Volumn 7, Issue 2, 2006, Pages 133-139

  Ellis, Charles N ^a   Kahler, Kristijan H ^b   Grueger, Jens ^b   Chang, Jane ^b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CLOBETASONE BUTYRATE; CORTICOSTEROID; DIFLUPREDNATE; HYDROCORTISONE BUTYRATE; HYDROCORTISONE VALERATE; PIMECROLIMUS; TRIAMCINOLONE ACETONIDE;

ADOLESCENT; ARTICLE; ATOPIC DERMATITIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; ECONOMIC ASPECT; HEALTH CARE COST; HUMAN; MULTICENTER STUDY; PHYSICIAN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADOLESCENT; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; TACROLIMUS;

EID: 33645880750     PISSN: 11750561     EISSN: 11750561     Source Type: Journal    
DOI: 10.2165/00128071-200607020-00006     Document Type: Article

References (33)

1. Kemp AS. Atopic eczema: its social and financial costs. J Paediatr Child Health 1999; 35: 229-31
2. Laughter D, Istvan JA, Tofte SJ, et al. The prevalence of atopic dermatitis in Oregon schoolchildren. J Am Acad Dermatol 2000; 43: 649-55
3. Ellis CN, Drake LA, Prendergast MM, et al. Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol 2002; 46: 361-70
4. Fivenson D, Goldberg Arnold RJ, Kaniecki DJ, et al. The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization. J Managed Care Pharm 2002; 8: 333-42
5. Ellis CN, Prendergast MM, Tokar M, et al. Quantifying costs associated with atopic dermatitis. J Managed Care Pharm 2003; 9: 278-9
6. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for the use of topical glucocorticosteroids. American Academy of Dermatology. J Am Acad Dermatol 1996; 35: 615-9
7. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments of atopic eczema. Health Technol Assess 2000; 4: 1-91
8. Van Der Meer JB, Glazenburg EJ, Mulder PG, et al. Management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic Dermatitis Study Group. Br J Dermatol 1999; 140: 1114-21
9. Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002; 147: 528-37
10. Paller AS, McAlister RO, Doyle JJ, et al. Perceptions of physicians and pediatric patients about atopic dermatitis, its impact, and its treatment. Clin Pediatr (Phila) 2002; 41: 323-32
11. Ellis C, Luger T, for the ICCAD Faculty. International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol 2003; 148 Suppl. 63: 3-10
12. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110: e2
13. McAlister RO, Tofte SJ, Doyle JJ, et al. Patient and physician perspectives vary on atopic dermatitis. Cutis 2002; 69: 461-6
14. Scott-Levin Staff, Editors. Physician drug and diagnosis audit, April 2000. Yardley (PA): Verispan, Inc., 2000
15. Centers for Medicare & Medicaid Services. 2001 national physician fee schedule relative value file. Baltimore, MD: Centers for Medicare & Medicaid Services; 2001
16. Mosteller RD. Simplified calculation of body-surface area [letter]. N Engl J Med 1987; 317: 1098
17. Medical Economics Staff, editors. 2001 drug topics red book. Montvale (NJ): Medical Economics Company, 2001
18. Friedman JY, Reed SD, Weinfurt KP, et al. Parents' reported preference scores for childhood atopic dermatitis disease states. BMC Pediatr 2004; 4: 21
19. Torrance GW. Social preferences for health states: an empirical evaluation of three measurement techniques. Socioecon Plann Sci 1976; 10: 129-36
20. Weinstein MC, Siegel JE, Gold MR, et al., for the Panel on Cost-Effectiveness in Health and Medicine. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 1253-8
21. Ellis CN, Reiter KL, Wheeler JRC, et al. Economic analysis in dermatology. J Am Acad Dermatol 2002; 46: 271-83
22. Bureau of Labor Statistics, US Department of Labor. Consumer price indexes [online]. Available from URL: http://www.bls.gov/cpi/ [Accessed 2006 Feb 15]
23. Torrance GW, Feeny DH, Furlong WJ, et al. Multiattribute utility function for a comprehensive health status classification system: Health Utilities Index Mark 2. Med Care 1996; 34: 702-22
24. Habif TP. Clinical dermatology. 4th ed. St Louis (MO): Mosby, Inc., 2004: 105-28
25. Lapidus CS, Schwarz DF, Honig PJ. Atopic dermatitis in children: who cares? Who pays? J Am Acad Dermatol 1993; 28: 699-703
26. Theunissen NC, Vogels TG, Koopman HM, et al. The proxy problem: child report versus parent report in health-related quality of life research. Qual Life Res 1998; 7: 387-97
27. Johnson N, Kahler K. Total cost of care for patients with pediatric atopic dermatitis [poster no. 121]. American Academy of Dermatology Annual Meeting; 2002 Feb 22-27; New Orleans (LA)
28. Weinberg JM. Formulary review of therapeutic alternatives for atopic dermatitis: focus on pimecrolimus. J Manag Care Pharm 2005; 11: 56-64
29. Su JC, Kemp AS, Varigos GA, et al. Atopic eczema: its impact on the family and financial cost. Arch Dis Child 1997; 76: 159-62
30. Newby LK, Eisenstein EL, Califf RM, et al. Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med 2000; 342: 749-55
31. Smith KJ, Roberts MS. The cost-effectiveness of sildenafil. Ann Intern Med 2000; 132: 933-7
32. Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA 2000; 283: 889-96
33. Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20: 332-42